Insilico Medicine CEO Alex Zhavoronkov details the company's massive $2.75 billion drug discovery deal with Eli Lilly and the shift to AI-native pharma pipelines. Alex Zhavoronkov, Ph.D. in the company’s Suzhou robotics lab. On March 29, Insilico Medicine announced a drug discovery deal with Eli Lilly that gives the Big Pharma firm an exclusive worldwide license to a portfolio of preclinical oral therapeutics. The collaboration also sets up joint R&D programs across a range of therapeutic areas. Under the terms of the deal, Insilico is eligible for a $115 million upfront payment, with milestones that would make the deal worth…
On March 29, Insilico Medicine announced a drug discovery deal with Eli Lilly that gives the Big Pharma firm an exclusive worldwide license to a portfolio of preclinical oral therapeutics. The collaboration also sets up joint R&D programs across a range of therapeutic areas. Under the terms of the deal, Insilico is eligible for a…
The post Insilico CEO sees potentially $2.75 billion collaboration as ‘fusing Lilly’s clinical excellence’ with Insilico’s ‘end-to-end AI engine’ appeared first on Drug Discovery and Development.
US Pharma Marketing